iCAD announces first recurrent GBM tumor treated with Xoft Brain IORT in US

iCAD announced that the first patient with recurrent glioblastoma, GBM, was treated with the Xoft Axxent Electronic Brachytherapy at Providence Saint John's Health Center in Santa Monica, CA. This procedure was part of the international multi-center GLIOX trial. The GLIOX trial is designed to compare Xoft IORT plus Avastin to the investigational arm of RTOG-1205. Researchers hope this study will validate the initial results from a prospective two center comparative study at the European Medical Center in Moscow, Russia. New Research Supports Innovative Therapy Approach. Data supporting Xoft Brain IORT for the treatment of recurrent GBM were recently published in study and a subsequent erratum in the peer-reviewed journal, Surgical Neurology International.The comparative study evaluated 15 patients with recurrent GBM who were treated with maximal safe resection and Xoft Brain IORT, and 15 patients with recurrent GBM treated with maximal safe resection and other modalities, between June 2016 and June 2019. As of March 2021, patients treated with Xoft Brain IORT lived for up to 54 months after treatment without recurrence, whereas patients in the control group had a recurrence within 10 months and lived for up to 22.5 months after treatment. Researchers also found there were fewer complications in the IORT group. One patient from the IORT group was still alive in fall 2021, whereas none of the patients in the control group survived. Additionally, a subgroup analysis of patients with postoperative tumors volumes of less than 2.5 cm showed more favorable outcomes for patients in the IORT group. "The researchers concluded that the results are encouraging and that further clinical trials are warranted," the company said. The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. The Xoft System is also currently being studied in the treatment of other types of brain tumors.